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Introduction
Post-transcriptional modifications, exemplified by alternative 
splicing, are regulatory mechanisms of biological processes that 
create enormous diversity in the proteins derived from a single 
gene.1,2 RNA editing is an additional post-transcriptional mech-
anism that also generates RNA and protein diversity. In mam-
mals, the most common form of RNA editing is substitution of 
adenosine (A) to inosine (I). Edited RNAs have consequently a 
sequence that is different from genomic DNA. RNA editing can 
selectively alter either coding or noncoding sequences in nuclear 
transcripts, including pre-mRNAs. A-to-I editing is catalyzed 
by the adenosine deaminases acting on RNA (ADARs) class 
of enzymes, which recognize unique double-stranded RNA 
structures containing bulges and loops. RNA editing may 
cause changes in alternative splicing patterns, microRNA inter-
action sites or even amino acids.3 Several reports highlighted 
that RNA editing can frequently occur in the brain, however in 
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tumors, these post-transcriptional events were found to be less 
pronounced compared with normal tissues.4-6
The Hedgehog (HH) signaling pathway is known to have 
important roles in diverse biological contexts, including embry-
onic development, stem cell maintenance and tumorigenesis. 
Deregulation of HH signaling results in developmental defects 
and different types of tumors. In these tumors, the pathway 
is abnormally upregulated, and effective signaling inhibition 
can repress tumor growth and induce apoptosis.7 The Glioma-
associated oncogene 1 (GLI1) is a transcription factor, which 
acts as a terminal effector of the HH signaling pathway, in addi-
tion to being a target gene. GLI1 has been characterized as an 
oncogene and its overexpression leads to basal cell carcinoma 
in transgenic mice.8 Recently, several reports highlighted that 
GLI1 acts as a key molecule in the regulation of tumor growth 
and the self-renewal of cancer stem cells.9,10
GLI1 expression and activity are known to be regu-
lated at different levels and include both transcriptional and 
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signaling activation, it is important to clarify the regulatory 
mechanisms that act on the GLI1 transcriptional activity.
In this study, we demonstrate that the GLI1 mRNA is also 
under the regulation of the post-transcriptional process of RNA 
editing, resulting in an amino acid change of the GLI1 protein 
with an impact on GLI1 activity. This editing event is prevalent 
in a number of tissues; however, in the corresponding tumors, 
the extent of GLI1 editing is reduced. These findings suggest 
post-transcriptional processes.11-15 These post-transcriptional 
mechanisms increase the functional diversity of the GLI1 pro-
tein and have an impact on the biological activity of GLI1, 
exemplified by the role of a GLI1 splice variant for glioblastoma 
and breast cancer cell migration and invasion.16,17 Moreover, 
GLI1 has been the focus of several recent attempts on can-
cer therapy as a novel molecular target.9,18-21 Consequently, to 
fully understand the functional implications of GLI1 for HH 
Figure 1A–B. Identification of RNA editing in GLI1. electropherograms of the sequence analysis of the RNA-edited region in GLI1. mRNAs from normal 
tissues (A) or medulloblastoma cell lines (B) were RT-pcR amplified and the products were analyzed by direct sequencing. Red triangles indicate the 
target nucleotide of RNA editing.
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neuroblastoma cell lines that exhibit detectable levels of GLI1 
editing were analyzed. Interestingly, knocking down of either 
ADAR1 or ADAR2 in SK-N-AS, SH-SY5Y, SK-N-BE(2) or 
SK-N-SH cells resulted in a reduction of adenosine 2179 deami-
nation in the cell lines examined (Fig. 2A–D).
Adenosine 2179 of human GLI1 is highly conserved in 
mammals, but the surrounding sequence has certain variations 
(Fig. 3A). These nucleotide substitutions could have an impact 
on the secondary structure of the mRNA and, thus, on RNA 
editing. The predicted secondary structures according to Mfold 
(www.mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form) 
highlight similar stem-loop patterns among the chimpanzee, 
the orangutan and the human GLI1 (Fig. 3B). However, in 
the marmoset, a more evolutionary distant primate, and in the 
mouse, different stem-loop patterns are observed (Fig. S2). In 
fact, we analyzed mouse Gli1 mRNAs from various sources but 
could not detect any evidence of RNA editing (Fig. S3). These 
observations may indicate that RNA editing of GLI1 could 
only occur in some primates.
The majority of A-to-I editing events have been predicted 
to occur in the UTR regions or in the introns, however there are 
also numerous cases that affect coding exons, including the glu-
tamate receptor and serotonin receptor mRNAs.23,24 The editing 
of GLI1 was found in the coding region, namely in the sequence 
encoding the C-terminal half of the protein (Fig. 3C). This 
base substitution results in an amino acid change at position 
701, from Arginine to Glycine, which may influence the sec-
ondary structure of the GLI1 protein (Fig. 3D). In fact, predic-
tion programs (the Consensus Secondary Structure Prediction 
www.npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/
npsa_seccons.html) indicate that this editing shortens the 
length of the α helix structure. This finding suggests that RNA 
editing could influence the biochemical properties of GLI1.
Biochemical characterization of the RNA-edited GLI1. To 
clarify the functional implications on GLI1 elicited by RNA edit-
ing, the edited GLI1, named GLI1-701G, was cloned into the 
mammalian expression vector, pCMV5. Transfection of the cloned 
construct into HEK293 cells revealed that the GLI1-701G protein 
was expressed at similar levels as the non-edited GLI1 (Fig. 4A). 
Moreover, the transcriptional activity, as determined by the 
12xGLIBS-luc reporter (Fig. 4B) and the mPtch1-1B-luc reporter 
(Fig. 4C), was slightly higher for GLI1-701G than for GLI1 at the 
range of 10–30 ng of transfected construct. However, with the use 
of the mGli1-luc reporter (Fig. 4D), the activity of GLI1-701G and 
GLI1 was equivalent. These findings indicate that GLI1-701G and 
GLI1 can have different transcriptional activities depending on the 
target gene or the DNA-binding sequence.
The RNA-edited target site exchanges an amino acid within a 
domain in the GLI1 C-terminal half that binds to the negative reg-
ulator of HH signaling, suppressor of fused (SUFU)25 (Fig. 3C). 
This implies that GLI1-701G may have a different susceptibility to 
inhibition by SUFU. To verify this possibility, we analyzed the GLI 
activity in the HH signaling constitutively active cell lines, Ptch1-
/- and Sufu-/- mouse embryonic fibroblasts (MEFs) (Fig. 4E). 
In Sufu-/- MEFs, GLI1-701G had a similar activity as GLI1. On 
the other hand, GLI1 showed reduced activity compared with 
that novel post-transcriptional mechanisms are involved in con-
trolling the functional impact of the terminal effector of HH 
signaling, the transcription factor GLI1.
Results
Identification of human GLI1 modification by RNA editing. 
A recent report on whole genome screening of RNA editing 
revealed that this post-transcriptional event is more frequent 
than previously anticipated. These observations highlighted 
that a large number of mRNAs, including GLI1, are edited 
in the brain.22 To confirm this finding, we analyzed the GLI1 
mRNA from human cerebellum and medulloblastoma cell lines 
(Fig. 1A and B). Our data revealed that the GLI1 mRNAs are 
highly edited by conversion of A to I at nucleotide position 2179 
(accession number NM_005269) in both fetal and adult cere-
bellum. However, in cell lines from the cerebellar tumor medul-
loblastoma, and in agreement with the postulate that tumors 
are characterized by hypoediting,4 this A to I substitution was 
almost negligible. Interestingly, the RNA editing of GLI1 was 
detected not only in brain but also in other tissues, including 
lung, colon, pancreas and ovary. In tumor cell lines though, 
originating from these tissues, the extent of editing was severely 
reduced (Fig. S1). Additionally, a single A peak was observed 
when genomic DNA from the medulloblastoma cell line that 
revealed detectable levels of RNA editing, the UW-228-3, was 
sequenced, ruling out the presence of a gene polymorphism 
(Fig. 1C). This is in agreement with the A/A genotype of more 
than 400 analyzed chromosomal samples from individuals of 
European, Asian and Sub-Saharan African descent (www.ncbi.
nlm.nih.gov/snp). Moreover, to check whether the reduction in 
RNA editing of GLI1 is not limited to cancer cell lines but also 
occurs in biopsy tumor specimen, basal cell carcinomas and 
control skin were also analyzed. In line with the observations 
described above, the extent of GLI1 editing was reduced in the 
tumor relative to the control samples (Fig. 1D).
To determine the role of the ADAR1 and ADAR2 enzymes 
in the adenosine deamination of nucleotide 2179, four 
Figure 1C. Genomic DNA sequence analysis of the GLI1 edited region 
in the UW-228-3 medulloblastoma cell line. The red triangle indicates 
the target nucleotide of RNA editing. Note the presence of a single A 
peak.
324 RNA Biology Volume 10 Issue 2
Figure 1D. mRNAs from six basal cell carcinoma and four control skin samples were RT-pcR amplified and the products were analyzed by direct 
sequencing. Red triangles indicate the target nucleotide of RNA editing.
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Figure 2A. Knockdown of ADAR1 or ADAR2 affects RNA editing of GLI1. electropherograms of the sequence analysis of the RNA-edited region in 
GLI1 in the four neuroblastoma cell lines sK-N-As (A), sh-sY5Y (B), sK-N-Be(2) (C) or sK-N-sh (D), following knockdown of ADAR1 or ADAR2. Note that 
knocking down of either ADAR1 or ADAR2 results in reduced RNA editing of GLI1. The effectiveness and specificity of the ADAR1 and ADAR2 knock-
downs, determined by real-time RT/pcR analysis, is shown for all four neuroblastoma cell lines.
Figure 2B. Knockdown of ADAR1 or ADAR2 affects RNA editing of GLI1. electropherograms of the sequence analysis of the RNA-edited region in 
GLI1 in the four neuroblastoma cell lines sK-N-As (A), sh-sY5Y (B), sK-N-Be(2) (C) or sK-N-sh (D), following knockdown of ADAR1 or ADAR2. Note that 
knocking down of either ADAR1 or ADAR2 results in reduced RNA editing of GLI1. The effectiveness and specificity of the ADAR1 and ADAR2 knock-
downs, determined by real-time RT/pcR analysis, is shown for all four neuroblastoma cell lines.
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Figure 2C. Knockdown of ADAR1 or ADAR2 affects RNA editing of GLI1. electropherograms of the sequence analysis of the RNA-edited region in 
GLI1 in the four neuroblastoma cell lines sK-N-As (A), sh-sY5Y (B), sK-N-Be(2) (C) or sK-N-sh (D), following knockdown of ADAR1 or ADAR2. Note that 
knocking down of either ADAR1 or ADAR2 results in reduced RNA editing of GLI1. The effectiveness and specificity of the ADAR1 and ADAR2 knock-
downs, determined by real-time RT/pcR analysis, is shown for all four neuroblastoma cell lines.
Figure 2D. Knockdown of ADAR1 or ADAR2 affects RNA editing of GLI1. electropherograms of the sequence analysis of the RNA-edited region in 
GLI1 in the four neuroblastoma cell lines sK-N-As (A), sh-sY5Y (B), sK-N-Be(2) (C) or sK-N-sh (D), following knockdown of ADAR1 or ADAR2. Note that 
knocking down of either ADAR1 or ADAR2 results in reduced RNA editing of GLI1. The effectiveness and specificity of the ADAR1 and ADAR2 knock-
downs, determined by real-time RT/pcR analysis, is shown for all four neuroblastoma cell lines.
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RNA editing has an impact on the subcellular distribution of 
GLI1, the GLI1 and GLI1-701G constructs were transfected 
into C3H10/T1/2 cells followed by immunofluorescence analy-
sis (Fig. 5). Both GLI1 variants were found to be localized in 
the cytoplasm and the nucleus. This result highlights that RNA 
editing does not confer a major change on GLI1 subcellular 
localization and the differences in the transcriptional activities 
of GLI1-701G / GLI1 are not likely to be due to alterations in 
cytoplasmic/nuclear distributions.
GLI1–701G in Ptch1-/- MEFs. Additionally, co-transfection with 
a SUFU expression construct in C3H10/T1/2 cells demonstrated 
that GLI1-701G is less susceptible to inhibition by SUFU relative 
to GLI1 (Fig. 4F). These differences were not large, yet represented 
significant changes that may be relevant for endogenous GLI1 
expression levels, which are usually very low.
Subcellular localization of GLI1-701G. Previous reports have 
shown that the subcellular localization of GLI1 can be critical for 
its capacity to act as a transcription factor.26 To examine whether 
Figure 3A–C. Impact of RNA editing on GLI1 protein structure. (A) comparison of the sequence of the RNA-edited region in GLI1 among different 
mammalian species. The target nucleotide of RNA editing in GLI1 and its orthologs is highlighted by a red box. Nucleotides in red indicate differ-
ences from the human sequence. (B) secondary structures of the RNA-edited region in human GLI1 (upper panel) and the corresponding ones in 
the chimpanzee (middle panel) and the orangutan (lower panel). The edited A nucleotide in human and the equivalent in the other two primates 
are highlighted by red triangles. Note that the edited nucleotide is positioned within the terminal exon 12 of the human GLI1, 524 nucleotides 3' of 
the splice junction. (C) predicted protein domains of GLI1. The protein processing site, sUFU-binding sites, zinc finger domains, activation domain, 
nuclear localization signals (NLs) and nuclear export signal (Nes) are shown. A red triangle indicates the target position of RNA editing.
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Discussion
Post-transcriptional biological processes are key regulatory 
events that increase the diversity of the transcriptome and the 
proteome. RNA editing is a post-transcriptional mechanism 
that alters nucleotide residues, with its most prevalent form in 
mammals being the A-to-I conversion. Double-stranded RNA 
structures harboring stem-loops are the targets of A-to-I edit-
ing, with most of these modifications occurring in untrans-
lated regions, introns or pre-miRNAs. However, RNA editing 
can also actively change nucleotides in the coding sequence of 
mRNAs and consequently expand the variability of the encoded 
proteins. Recent reports have demonstrated that thousands of 
human genes are subjected to A-to-I RNA editing. This nucleo-
tide modification is most abundantly observed in brain tissues, 
and dysfunction of RNA editing has been related to neuro-
logical disorders. Accumulated evidence is therefore suggest-
ing that RNA editing is an important regulatory mechanism 
with an impact on diverse biological processes. However, the 
specific roles and outcomes of individual RNA editing events 
have been analyzed only in a limited number of genes or cel-
lular contexts.3,22,29,30 In this study, we demonstrate abundant 
A-to-I RNA editing in the coding region of the GLI1 oncogene 
in normal human tissues, reduced editing in the correspond-
ing cancer cells and provide biochemical evidence for the role 
of this post-transcriptional modification as a novel regulatory 
mechanism that modulates GLI1 activity.
Worth noting is that knocking down of either ADAR1 or 
ADAR2 reduces the deamination of adenosine 2179 in all four 
cell lines analyzed (Fig. 2). This observation highlights the 
requirement of both ADAR1 and ADAR2 for effective editing of 
the GLI1 mRNA. One scenario that could provide a mechanistic 
interpretation of this finding is the formation of ADAR1/ADAR2 
heterodimers31 that are catalytically active on this substrate.
Recently, Joost et al. showed that low level of GLI1 expression 
in pancreatic cancer cells is related to epithelial-to-mesenchymal 
transition, while high expression promotes epithelial differ-
entiation.32 Consequently, GLI1 may have different functions 
depending on its expression level. Our data indicate that in nor-
mal tissues, where GLI1 expression is usually very low, GLI1 is 
frequently modified by RNA editing. Moreover, when GLI1 was 
overexpressed in non-cancer cell lines, no major differences in the 
transcriptional activities of GLI1 and GLI1-701G were observed 
at higher levels of expression. However, we clearly detected that 
GLI1 and GLI1-701G have distinct transcriptional capacities at 
lower levels of expression. Thus, it is likely that in the context of 
normal adult tissues, characterized by low GLI1 expression, RNA 
editing of GLI1 may be functionally significant.
A different scenario is probably taking place in GLI1-
dependent cancer cells. RNA editing of GLI1 is very low, GLI1 
expression is relatively high and the non-edited GLI1 has been 
shown to be the major target of the GLI1 activating Dyrk1a 
kinase. The proliferative advantage elicited by overexpression of 
GLI1 compared with GLI1-701G is also in-line with the impact 
of the non-edited GLI1 in cancer cells. Moreover, the inverse 
correlation between GLI1 levels and the extent of RNA editing 
Biological significance of RNA editing. GLI1 is also known 
to be regulated by phosphorylation. Dyrk1a is reported to be 
a kinase, with an apparent role in neuroblast proliferation,27 
which modifies the GLI1 activity.28 To examine the impact 
of RNA editing of GLI1 on the Dyrk1a effects, we co-trans-
fected Dyrk1a with GLI1 or GLI1-701G. In C3H10/T1/2 
cells, Dyrk1a activated only GLI1, while in NIH3T3 cells, the 
activity of both variants was increased, but to a lesser extent 
for GLI1-701G (Fig. 6A). Thus, in two cellular contexts, RNA 
editing of GLI1 reduces its responsiveness to the Dyrk1a kinase.
GLI1 functions as an oncogene, and inhibition or knock-
down of GLI1 negatively affects tumor cell growth.18-21 
However, our data suggest that GLI1 editing is frequently 
observed in normal cells but not in tumor cells. Therefore, 
we hypothesized that RNA editing of GLI1 might reduce the 
impact of this oncogenic factor on cellular growth. To test this 
hypothesis, we introduced the GLI1 or GLI1-701G expression 
constructs, together with pEGFP, into the medulloblastoma 
cell line D283Med. As anticipated, GLI1-701G compared with 
GLI1, resulted in a decreased percentage of EGFP-positive cells 
after 3 d of cellular growth (Fig. 6B).
Taken together, these results indicate that RNA editing acts 
as a novel modifier of the HH signaling pathway via its impact 
on the GLI1 transcription factor.
Figure 3D. (D) Influence of RNA editing on the GLI1 protein structure. 
The predicted secondary structure of the GLI1 protein was calculated 
by the use of several algorithms. The R-to-G amino acid substitution at 
position 701 that is elicited by RNA editing is shown by red triangles. The 
abbreviations are: h, α helix; e, extended strand; c, random coil; t: β turn; 
?, ambiguous state. Note the decreased α helix structure in the 690–710 
region of the edited GLI1.
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in normal and tumor cells implies that this post-transcriptional 
modification may act as a “protective barrier” that has to be over-
come in the process of tumorigenesis. Whether efforts to increase 
the frequency of GLI1 editing in tumors can have a therapeutic 
significance remains to be seen.
In summary, our findings demonstrate a novel regulatory 
mechanism that acts on the GLI1 oncogene, as summarized in 
the model of Figure 7. RNA editing of GLI1 alters its susceptibil-
ity to both the negative HH signaling regulator SUFU and the 
positive regulator Dyrk1a. This post-transcriptional modification 
of GLI1 may therefore affect the biological outcomes of the HH 
signal transduction cascade.
Materials and Methods
Validation of GLI1 RNA editing. cDNAs and genomic DNA 
was amplified by initial and then nested primers, designed 
Figure 4A–D. (A–D) Biochemical characterization of the RNA edited GLI1. (A) protein expression following transfection of pcMV5, FLAG-tagged GLI1 
and FLAG-tagged GLI1-701G into heK293 cells. Western blotting was performed using an anti-FLAG antibody. α/β-Tubulin expression and coomassie 
brilliant blue staining (cBB) are also shown as loading controls. (B–D) Luciferase activity of the GLI1 and GLI1-701G constructs in c3h10/T1/2 cells. One 
to 100 ng of the GLI1 expression constructs were transfected with 200 ng of 12xGLIBs-luc (B), mptch1 promoter-luc (C) or mGli1 promoter-luc (D). The 
error bars indicate the standard deviation, with the experiment done in triplicate.
within GLI1 exon 10, exon 11 and exon 12 (Table S1). Multiple 
tissue and cancer cell line cDNA panels from BD Biosciences 
were also used as a template. Each PCR reaction consisted of 
1x standard Taq buffer, 0.2 mM for each dNTP, 1 μM for-
ward primers, 1.0 μM reverse primer, 0.5 μl of Taq DNA 
polymerase (5 units/μl, New England Biolabs) and 1 ng of 
cDNA in a total volume of 25 μl. Twenty cycles with 20 sec at 
95°C, 20 sec at 66°C and 1 min at 72°C were performed on a 
Perkin-Elmer thermocycler. For nested PCR, 0.5 μl of the ini-
tial amplification products was used. Thirty cycles with 20 sec 
at 95°C, 20 sec at 66°C and 45 sec at 72°C were performed 
on a Perkin-Elmer thermocycler. The PCR products from the 
cDNAs (698 bp) and the genomic DNA (1,291 bp) were iso-
lated by agarose gel electrophoresis, and then purified products 
were sequence-verified.
Knockdown of ADAR1 and ADAR2. Predesigned siR-
NAs targeting human ADAR1 and ADAR2 (ADARB1) 
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plasmid, we first performed a PCR amplification using the 
ThermoPol Reaction buffer (New England Biolabs) on a full-
length 3'-FLAG-tagged human GLI1 expression plasmid in 
pCMV5, with a GLI1 primer (5'- CACTGAGAATGCTGC 
CATGGATGCTG) and a vector primer (5'- ACAAGGCTG 
GTGGGCACT). The PCR product and the FLAG-tagged 
GLI1 expression construct were digested with SalI and BsmI 
restriction enzymes and then ligated together. To make the 
mouse Gli1-luc reporter construct (mGli1-luc), the mouse 
Gli1 promoter region was first cloned into the pGL4.21 vector 
(Promega) and then the -572 to +1,346 region was subcloned 
into the pGL3-basic reporter vector.
Cell culture and reporter assays. The human embryonic kid-
ney cell line Hek293, the murine fibroblast cell lines NIH3T3 
and C3H10T1/2 and the MEF cell lines with the negative 
regulators of HH signaling Ptch1 and Sufu genetically elimi-
nated, Ptch1-/- 33 and Sufu-/- 34 MEFs were cultured as described 
before.35,36 The human medulloblastoma cell line D283Med 
was cultured according to the ATCC-LGC Promochem 
were purchased from Dharmacon (SiGenome SMART pools, 
Thermo Scientific). As controls, non-targeting siRNA pools 
from Dharmacon (SiGenome Non-Targeting siRNA control 
pools, Thermo Scientific) were used. Cells were plated in 6-well 
dishes at 50–60% confluency, and transfections were per-
formed with Lipofectamine 2000 (Invitrogen) and 150 pmol 
siRNA. After 48 h, total RNA was prepared with the RNeasy 
kit (Qiagen) followed by cDNA synthesis with random (N6) 
primers (New England Biolabs) and Superscript II (Invitrogen). 
Real-time RT-PCR was performed with Power SYBR Green 
(Applied Biosystems) on a 7,500 fast real-time PCR system 
(Applied Biosystems) with the primers used shown in Table S2. 
mRNA expression levels were normalized against the house-
keeping genes RPLPO and TBP, and the expression relative to 
the control siRNA sample, which is assigned to 1, is shown.
Subcloning of expression and reporter constructs. For 
construction of the 3'-FLAG-tagged GLI1-701G expression 
Figure 4E–F. (E) GLI activities in hh signaling active cell lines. The GLI1 
or GLI1-701G expression constructs (10–50 ng) were transfected with 
12xGLIBs-luc (200 ng) into ptch1-/- MeFs or sufu-/- MeFs. The error 
bars indicate the standard deviation, with the experiment replicated 
four times. (F) Inhibition of GLI1 activities by sUFU. The GLI1 or GLI1–
701G expression constructs (50 ng) were transfected into c3h10T1/2 
cells with a sUFU expression construct (10–250 ng) and 12xGLIBs-luc 
(200 ng), and the luciferase activity of the 12xGLIBs-luc reporter was 
measured. The control values represent GLI1 activities without sUFU. 
The error bars indicate the standard deviation, with the experiment 
done in duplicate. In the figure panels, the asterisks represent statistical 
significance calculated by the Welch’s t-test (p < 0.05).
Figure 5. subcellular localization of the RNA-edited GLI1. The FLAG-
tagged GLI1-701G and GLI1 constructs were transfected into c3h10/
T1/2 cells and expressed proteins (green signal) and the nuclei stained 
with the marker DRAQ5 (blue signal) were visualized by immunofluo-
rescence microscopy. Note the similar subcellular localization in both 
the cytoplasm and nucleus of GLI1-701G and GLI1.
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recommendation. GLI1 activity was measured by the dual-lucif-
erase assay kit (Promega), as described before.13 Expression con-
structs for GLI1,13 SUFU25,26 or Dyrk1a,28 and the appropriate 
reporter construct, the 12xGLIBS-luc,28 the mouse Ptch1-1B-luc 
(mPtch1-1B-luc)13 or the mGli1-luc, together with the renilla 
luciferase pRL-SV construct, were transfected into cultured cells 
using FuGENE 6 (Roche Diagnostics). All experiments were 
performed at least three times.
Western blotting. Forty-eight hours after transfection, pro-
teins were extracted by lysis buffer [50 mM Tris (pH 7.4), 1% 
SDS, 250 mM NaCl, 2 mM dithiothreitol, 0.5% Nonidet P-40, 
1% phosphatase inhibitor mixture 1 (Sigma), and 1% mamma-
lian protease inhibitor mixture (Sigma)]. After normalization 
based on protein concentration measured by the DC protein 
assay kit (Bio-Rad), samples were run on a SDS-acrylamide 
gel. Thereafter, proteins were transferred onto Hybond-ECL 
nitrocellulose membrane (GE Healthcare). GLI1 variants or 
α/β-tubulin as internal control were determined by the use 
of anti-FLAG monoclonal (Stratagene) or α/β-tubulin rabbit 
Figure 6. Biological effects of the RNA edited GLI1. (A) Regulation of GLI1 by Dyrk1a. The FLAG-tagged GLI1-701G or GLI1 expression constructs were 
co-transfected with a Dyrk1a expression construct into c3h10/T1/2 and NIh3T3 cells. The luciferase activity of the 12xGLIBs-luc reporter  
was measured. The error bars indicate the standard deviation, with the experiment done in triplicate. The asterisk represents statistical significance 
calculated by the student’s t-test (p < 0.01). (B) effect of GLI1 on the proliferation of medulloblastoma cells. peGFp (0.5 μg) vector and FLAG-tagged 
GLI1-701G or GLI1 expression constructs (1.5 μg) were transfected into the D283Med medulloblastoma cell line. After 3 d of incubation, eGFp-positive 
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